Adapt Pharma, the Dublin, Ireland-based drug company, has appointed Mike Kelly as president of U.S. operations, located in Radnor, writes John George of the Philadelphia Business Journal.
The company is renowned as the maker of the Narcan nasal spray used to treat patients suffering from overdoses of heroin and other opioid medicines.
Kelly will be responsible for all of the company’s operating activities in the U.S., and will report to Eunan Maguire, chief operating officer of Adapt Pharma.
Before joining Adapt Pharma, Kelly, who has nearly three decades of pharmaceutical company experience, was CEO at Covis Pharmaceuticals in North Carolina. He was also a member of the founding management team of Azur Pharma, which was acquired by Jazz Pharmaceuticals of California in 2011.
“Mike has established a highly successful track record in leadership roles in specialty pharmaceuticals,” said Seamus Mulligan, chairman and CEO of Adapt Pharma. “His experience will be of great value as Adapt Pharma expands its commercial presence, starting with the launch of Narcan nasal spray.”
The Food and Drug Administration approved Narcan nasal spray, which is designed to stop or reverse the effects of opioid overdoses, in late 2015.
Click here to read more about Adapt Pharma.